
Jiaxin (Jason) Niu, MD, explains which patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit most from combination therapy over osimertinib monotherapy, citing brain metastases, liver metastases, elevated baseline ctDNA, and TP53 co-mutation as high-risk features present in up to 80% to 90% of patients.


















